Acute Lymphoblastic Leukemia: Therapy, excluding Transplantation: Improving Frontline Therapy in ALL

31  Nilotinib (Tasigna®) and Low Intensity Chemotherapy for First-Line Treatment of Elderly Patients with BCR-ABL1- Positive Acute Lymphoblastic Leukemia: Final Results of a Prospective Multicenter Trial (EWALL-PH02)

Oliver G. Ottmann, et al.

The Abstract concludes: Nilotinib combined with low-intensity chemotherapy is well tolerated and highly effective in elderly pts. with Ph-positive ALL. OS and EFS compare favorably with previous similar studies testing imatinib or dasatinib. With 32% of pts. undergoing allogeneic HSCT and 61% survival at 4 years, transplantation is a viable option in this elderly cohort of pts..

32  A Phase II Study of the Hyper-CVAD Regimen in Sequential Combination with Blinatumomab As Frontline Therapy for Adults with B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Guillaume Richard-Carpentier, et al.

The Abstract concludes: The sequential combination of Hyper-CVAD and blinatumomab in newly diagnosed adult patients with B-ALL is safe and highly effective. These early results are favorable. The study continues to accrue patients.

33  Results of SWOG 1318: A Phase 2 Trial of Blinatumomab Followed By Pomp (Predni-sone, Vincristine, Methotrexate, 6-Mercaptopurine) Maintenance in Elderly Patients with Newly Diagnosed Philadelphia Chromosome Negative B-Cell Acute Lymphoblastic Leukemia

Anjali S. Advani, et al.

The Abstract concludes: Blinatumomab was well tolerated and effective in the treatment of newly diagnosed elderly patients with Ph negative B-lineage ALL. Further follow up will determine the durability of these responses.

34  Inotuzumab Ozogamicin in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) Vs. Standard Intensive Chemotherapy (hyper-CVAD) As Frontline Therapy for Older Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL): A Propensity Score Analysis

Koji Sasaki, MD,et al.

The Abstract concludes: The combination of inotuzumab ozogamicin with low-intensity therapy is safe and effective in elderly patients with newly diagnosed Philadelphia-negative ALL, and confers better outcome when compared with standard HCVAD chemotherapy.

35  Triple Intrathecal Therapy (Methotrexate/Hydrocortisone/Cytarabine) Does Not Improve Disease-Free Survival Versus Intrathecal Methotrexate Alone in Children with High Risk B-Lymphoblastic Leukemia: Results of Children's Oncology Group Study AALL1131

Wanda L. Salzer, et al.

The Abstract concludes: The administration of post-induction age adjusted ITT did not improve 5-year DFS of children with HR B‑ALL without CNS leukemia. IT MTX remains the standard of care for CNS prophylaxis.

36  Chemoimmunotherapy with Inotuzumab Ozogamicin Combined with Mini-Hyper-CVD, with or without Blinatumomab, for Newly Diagnosed Older Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: Results from a Phase II Study

Nicholas J Short, et al.

The Abstract concludes: Mini-hyper-CVD + INO ± blinatumomab, is safe and effective in elderly pts with newly diagnosed Ph-negative ALL, with an overall response rate of 98% and 3-year OS rate of 54%.